FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381598176> ?p ?o ?g. }

• W4381598176 endingPage "32" @default.
• W4381598176 startingPage "22" @default.
• W4381598176 abstract "Coinfection with hepatitis D virus (HDV) accelerates the progression of liver disease associated with chronic hepatitis B. Bulevirtide inhibits the entry of HDV into hepatocytes. Download a PDF of the Research Summary. In this ongoing phase 3 trial, patients with chronic hepatitis D, with or without compensated cirrhosis, were randomly assigned, in a 1:1:1 ratio, to receive bulevirtide subcutaneously at 2 mg per day (2-mg group) or 10 mg per day (10-mg group) for 144 weeks or to receive no treatment for 48 weeks followed by bulevirtide subcutaneously at 10 mg per day for 96 weeks (control group). Patients will complete 96 weeks of additional follow-up after the end of treatment. The primary end point was a combined response at week 48 of an undetectable HDV RNA level, or a level that decreased by at least 2 log10 IU per milliliter from baseline, and normalization of the alanine aminotransferase (ALT) level. The key secondary end point was an undetectable HDV RNA level at week 48, in a comparison between the 2-mg group and the 10-mg group. A total of 49 patients were assigned to the 2-mg group, 50 to the 10-mg group, and 51 to the control group. A primary end-point response occurred in 45% of patients in the 2-mg group, 48% in the 10-mg group, and 2% in the control group (P<0.001 for the comparison of each dose group with the control group). The HDV RNA level at week 48 was undetectable in 12% of patients in the 2-mg group and in 20% in the 10-mg group (P=0.41). The ALT level normalized in 12% of patients in the control group, 51% in the 2-mg group (difference from control, 39 percentage points [95% confidence interval {CI}, 20 to 56]), and 56% in the 10-mg group (difference from control, 44 percentage points [95% CI, 26 to 60]). Loss of hepatitis B virus surface antigen (HBsAg) or an HBsAg level that decreased by at least 1 log10 IU per milliliter did not occur in the bulevirtide groups by week 48. Headache, pruritus, fatigue, eosinophilia, injection-site reactions, upper abdominal pain, arthralgia, and asthenia were more common in the 2-mg and 10-mg groups combined than in the control group. No treatment-related serious adverse events occurred. Dose-dependent increases in bile acid levels were noted in the 2-mg and 10-mg groups. After 48 weeks of bulevirtide treatment, HDV RNA and ALT levels were reduced in patients with chronic hepatitis D. (Funded by Gilead Sciences; MYR 301 ClinicalTrials.gov number, NCT03852719.) QUICK TAKE VIDEO SUMMARYBulevirtide for Chronic Hepatitis D 02:03" @default.
• W4381598176 created "2023-06-23" @default.
• W4381598176 creator A5001376175 @default.
• W4381598176 creator A5005950789 @default.
• W4381598176 creator A5007526376 @default.
• W4381598176 creator A5023363049 @default.
• W4381598176 creator A5024229375 @default.
• W4381598176 creator A5024581579 @default.
• W4381598176 creator A5026399951 @default.
• W4381598176 creator A5027668597 @default.
• W4381598176 creator A5030416479 @default.
• W4381598176 creator A5030437694 @default.
• W4381598176 creator A5034593215 @default.
• W4381598176 creator A5041536838 @default.
• W4381598176 creator A5043318824 @default.
• W4381598176 creator A5044587750 @default.
• W4381598176 creator A5045504446 @default.
• W4381598176 creator A5048918542 @default.
• W4381598176 creator A5049290481 @default.
• W4381598176 creator A5050079986 @default.
• W4381598176 creator A5050609377 @default.
• W4381598176 creator A5054909457 @default.
• W4381598176 creator A5066724683 @default.
• W4381598176 creator A5074836130 @default.
• W4381598176 creator A5076739762 @default.
• W4381598176 creator A5084376310 @default.
• W4381598176 creator A5085573931 @default.
• W4381598176 creator A5085961973 @default.
• W4381598176 date "2023-07-06" @default.
• W4381598176 modified "2023-10-16" @default.
• W4381598176 title "A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D" @default.
• W4381598176 cites W1559776411 @default.
• W4381598176 cites W1579006740 @default.
• W4381598176 cites W1963687802 @default.
• W4381598176 cites W1966807894 @default.
• W4381598176 cites W1997270466 @default.
• W4381598176 cites W2027032176 @default.
• W4381598176 cites W2065614359 @default.
• W4381598176 cites W2071993332 @default.
• W4381598176 cites W2073237899 @default.
• W4381598176 cites W2088160623 @default.
• W4381598176 cites W2120426460 @default.
• W4381598176 cites W2133202656 @default.
• W4381598176 cites W2147456300 @default.
• W4381598176 cites W2156213027 @default.
• W4381598176 cites W2173698250 @default.
• W4381598176 cites W2396178441 @default.
• W4381598176 cites W2398313845 @default.
• W4381598176 cites W2592457451 @default.
• W4381598176 cites W2617224210 @default.
• W4381598176 cites W2907871374 @default.
• W4381598176 cites W2915619471 @default.
• W4381598176 cites W3009935587 @default.
• W4381598176 cites W3010173717 @default.
• W4381598176 cites W3019175774 @default.
• W4381598176 cites W3044569778 @default.
• W4381598176 cites W3125570668 @default.
• W4381598176 cites W3155620769 @default.
• W4381598176 cites W3201993415 @default.
• W4381598176 cites W3207184595 @default.
• W4381598176 cites W4206715796 @default.
• W4381598176 cites W4281609246 @default.
• W4381598176 cites W4292998562 @default.
• W4381598176 cites W4295838443 @default.
• W4381598176 doi "https://doi.org/10.1056/nejmoa2213429" @default.
• W4381598176 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37345876" @default.
• W4381598176 hasPublicationYear "2023" @default.
• W4381598176 type Work @default.
• W4381598176 citedByCount "12" @default.
• W4381598176 countsByYear W43815981762023 @default.
• W4381598176 crossrefType "journal-article" @default.
• W4381598176 hasAuthorship W4381598176A5001376175 @default.
• W4381598176 hasAuthorship W4381598176A5005950789 @default.
• W4381598176 hasAuthorship W4381598176A5007526376 @default.
• W4381598176 hasAuthorship W4381598176A5023363049 @default.
• W4381598176 hasAuthorship W4381598176A5024229375 @default.
• W4381598176 hasAuthorship W4381598176A5024581579 @default.
• W4381598176 hasAuthorship W4381598176A5026399951 @default.
• W4381598176 hasAuthorship W4381598176A5027668597 @default.
• W4381598176 hasAuthorship W4381598176A5030416479 @default.
• W4381598176 hasAuthorship W4381598176A5030437694 @default.
• W4381598176 hasAuthorship W4381598176A5034593215 @default.
• W4381598176 hasAuthorship W4381598176A5041536838 @default.
• W4381598176 hasAuthorship W4381598176A5043318824 @default.
• W4381598176 hasAuthorship W4381598176A5044587750 @default.
• W4381598176 hasAuthorship W4381598176A5045504446 @default.
• W4381598176 hasAuthorship W4381598176A5048918542 @default.
• W4381598176 hasAuthorship W4381598176A5049290481 @default.
• W4381598176 hasAuthorship W4381598176A5050079986 @default.
• W4381598176 hasAuthorship W4381598176A5050609377 @default.
• W4381598176 hasAuthorship W4381598176A5054909457 @default.
• W4381598176 hasAuthorship W4381598176A5066724683 @default.
• W4381598176 hasAuthorship W4381598176A5074836130 @default.
• W4381598176 hasAuthorship W4381598176A5076739762 @default.
• W4381598176 hasAuthorship W4381598176A5084376310 @default.
• W4381598176 hasAuthorship W4381598176A5085573931 @default.
• W4381598176 hasAuthorship W4381598176A5085961973 @default.
• W4381598176 hasConcept C126322002 @default.

• next